Eli Lilly (LLY) Total Non-Current Liabilities (2009 - 2026)

Eli Lilly (LLY) has reported Total Non-Current Liabilities for 18 consecutive years, with $48.7 billion the latest figure, recorded in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $48.7 billion, up 12.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.7 billion (up 12.12% YoY), and the FY2025 annual result was $50.7 billion, up 40.61% from the prior year.
• Total Non-Current Liabilities was $48.7 billion for Q1 2026 at Eli Lilly, down from $50.7 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $50.9 billion in Q3 2025 and troughed at $21.6 billion in Q4 2022.
• Average Total Non-Current Liabilities over 5 years is $33.2 billion, with a median of $31.1 billion recorded in 2024.
• Year-over-year, Total Non-Current Liabilities slipped 18.49% in 2022 and soared 48.77% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $21.6 billion in 2022, then advanced by 19.81% to $25.8 billion in 2023, then jumped by 39.53% to $36.1 billion in 2024, then soared by 40.61% to $50.7 billion in 2025, then decreased by 3.88% to $48.7 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $48.7 billion in Q1 2026, $50.7 billion in Q4 2025, and $50.9 billion in Q3 2025.